Introduction
============

Clinical reports indicate that human females are more susceptible to nicotine addiction and have greater difficulty quitting the use of tobacco products than males.[@b1-jen-7-2013-001]--[@b4-jen-7-2013-001] Adolescent females are particularly vulnerable to nicotine addiction,[@b5-jen-7-2013-001],[@b6-jen-7-2013-001] as are young female rats.[@b7-jen-7-2013-001]--[@b11-jen-7-2013-001] Conditioned place preference (CPP) is a frequently utilized protocol for determining the dependence and reward potential of a compound in animal models;[@b12-jen-7-2013-001],[@b13-jen-7-2013-001] however, there have been conflicting results concerning nicotine-induced CPP, particularly as related to dose. A wide range of doses have been reported to produce CPP in rats,[@b14-jen-7-2013-001]--[@b18-jen-7-2013-001] with CPP absent at doses lower than 0.1 and higher than 1 mg/kg.[@b19-jen-7-2013-001]-- [@b26-jen-7-2013-001] We recently determined that adolescent female Sprague-Dawley rats showed CPP to a nicotine dose of 0.03 mg/kg,[@b27-jen-7-2013-001] significantly lower than the optimal dose of 0.6 mg/kg seen with adolescent female Wistar rats, as reported by Torres and colleagues.[@b18-jen-7-2013-001]

The addictive process appears to depend upon underlying alterations in the structural remodeling of synaptic connections.[@b28-jen-7-2013-001],[@b29-jen-7-2013-001] Thus, drugs of abuse modify learning-dependent changes in synaptic structure and function such that even after prolonged abstinence drug related cues are sufficiently salient to trigger drug seeking behavior.[@b30-jen-7-2013-001]--[@b32-jen-7-2013-001] Once memories are consolidated they continue to be subject to reconsolidation following reactivation.[@b33-jen-7-2013-001]--[@b35-jen-7-2013-001] Recent studies have shown that the disruption of the biochemical processes required for reconsolidation leads to an attenuation of drug seeking behavior.[@b25-jen-7-2013-001],[@b36-jen-7-2013-001]--[@b38-jen-7-2013-001] Thus, targeting the molecules involved in memory consolidation and reconsolidation, (eg, matrix metalloproteinases \[MMPs\]), could represent a useful strategy for blunting persistent drug dependence. MMPs are known to modify the extracellular matrix (ECM) proteins involved in regulating cytoskeletal reorganization and transcriptional activity; they also modify activation of proteases such as plasmin.[@b39-jen-7-2013-001]--[@b42-jen-7-2013-001] We reasoned that if changes in MMP expression are required for the consolidation/reconsolidation of drug-related memories, then the inhibition of MMP activity may disrupt the development of drug dependence and context dependent relapse.

The present investigation measured MMP-2, -3, and -9 expression, and the intracellular cytoskeletal protein cortactin,[@b43-jen-7-2013-001],[@b44-jen-7-2013-001] in the hippocampus (HIP) and prefrontal cortex (PFC) during acquisition and context dependent relapse of nicotine-induced CPP in adolescent female rats. We selected these MMPs based on previous work from our laboratory and other laboratories indicating their importance in learning and memory. Furthermore, these MMPs are the most abundant in the mammalian brain,[@b45-jen-7-2013-001],[@b46-jen-7-2013-001] and Cortactin has also been implicated in memory consolidation.[@b47-jen-7-2013-001] Based on previous results, the intracerebroventricular (ICV) infusion of the broad spectrum MMP inhibitor, FN439, was predicted to disrupt acquisition of drug associated learning and memory.[@b48-jen-7-2013-001],[@b49-jen-7-2013-001]

Materials and Methods
=====================

All experiments adhered to the Guidelines for the Care and Use of Laboratory Animals, as required by the National Institutes of Health (NIH Publication No. 80--23); the protocols were approved by the Washington State University Institutional Animal Care and Use Committee.

Subjects
--------

Four-week-old female Sprague-Dawley rats (breeding stock derived from Taconic, Germantown, NY) were housed 4--5 per cage in a room controlled for temperature and humidity and adapted to a 12 hour light-- dark cycle. The cycle was initiated at 0600 hours in an American Association of Laboratory Animal Care approved vivarium at a temperature of 21 °C ± 1 °C. All animals had ad libitum access to Purina laboratory rat chow and water, except the night before surgery when food was removed from the cage.

Reagents
--------

Nicotine hydrogen tartrate salt and FN439 were purchased from Sigma-Aldrich (Catalog \# N5260 and \#A4336, respectively, St. Louis, MO).

Surgical protocol
-----------------

Rats were anesthetized using ketamine hydrochloride plus xylazine (100 and 2 mg/kg respectively, i.m.) and a chronic ICV guide cannula was positioned as described by Pederson et al.[@b50-jen-7-2013-001] The scalp was shaved and cleaned with Betadine and 70% alcohol. A 4 cm midline incision superior on the skull was made and the scalp retracted. A trephine hole was placed with flat skull coordinates of 1 mm posterior to bregma and 1.5 mm lateral to the midline, per the atlas of Paxinos and Watson.[@b51-jen-7-2013-001] A guide cannula fashioned from PE-60 tubing (Clay Adams, Parsippany, NJ), prepared with a heat bulge 2.5 mm above its beveled tip, was stereotaxically inserted and held in place using skull screws (\#1--72 × 3/16′, Small Parts, Miami Lakes, FL) and dental acrylic (Lang Dental Supply, Wheeling, IL). The animals were allowed to recover for 5 days. Prior to CPP training, cannula placement was confirmed by a drinking response elicited by the ICV administration of angiotensin II (Catalog \# A9525, Sigma-Aldrich, 100 pmol in 2 μl sterile artificial cerebrospinal fluid vehicle \[aCSF: 124 mm NaCl, 3 mm KCl, 1.24 mm Na~2~PO~4~, 1.3 mm MgSO~4~, 2.0 mm CaCl~2~, 26 mm NaHCO~3~, 10 mm d-glucose\] with pH set at 7.4). This dose of angiotensin II generally elicits a very reliable drinking response within 5 minutes of infusion if guide cannula placement is correct. Non-responding animals were removed from the study.[@b52-jen-7-2013-001] We did not have to remove any rats from this study based on this testing criterion. All ICV infusions were accomplished using a hand held 10 μl Hamilton syringe connected by a 30 cm length of PE-20 tubing to a stainless steel tubing injector (31 gauge, 5.8 cm in length). Once inserted into the guide cannula the injector extended 3 mm beyond its tip, thus penetrating the roof of the lateral ventricle. Cannulas, injectors, and tubing were sterilized by overnight placement in CidexPlus (Johnson & Johnson, Arlington, TX). The infusant was delivered over a duration of 20 seconds. The injector was left in place for an additional 30 seconds before removal to avoid back flow.

Conditioned place preference protocol
-------------------------------------

The CPP apparatus consisted of a box 64 (L) × 20.5 (W) × 40 (H) cm constructed of wood and Plexiglas with two main compartments (28 × 20.5 cm) separated by a smaller compartment (8 × 20.5 cm). One of the main compartments was painted black and the other white. The black compartment had wire mesh flooring (1.2 cm squares) and the white compartment's floor consisted of parallel metal rods (diameter = 4.8 mm) spaced 1 cm apart. The central compartment had a black wooden floor. A 15 W lamp was placed over the black compartment to compensate for high initial preference. A video camera was placed directly over the apparatus to record the activity of the rat. The camera was connected to a computer which recorded the activity; this activity was interpreted by video tracking software that provided quantifiable information on locomotive activity, time spent in each compartment, and number of entries into a compartment (San Diego Instruments software package). A biased paradigm was used in which the animal was assigned to the non-preferred compartment following nicotine administration. This protocol is thought to be more effective at producing CPP than the unbiased procedure in which the animal is randomly assigned to a chamber after nicotine injection.[@b47-jen-7-2013-001]--[@b49-jen-7-2013-001]

During preconditioning the rats were placed in the middle compartment and allowed free access to the entire box for 15 minutes. The time spent in each compartment was noted. The animals underwent preconditioning for 2 days and the mean of the two sessions for each animal was calculated for each compartment.

The conditioning phase began the day following preconditioning and at the same time of day for each animal. Three major groups of rats received two conditioning sessions per day, for 5 consecutive days. During one session members of Group 1 (FN439-Nic) were ICV infused with FN439 (14 μg in 2 μl of aCSF over 20 seconds, and then a delay of 30 seconds prior to removal of the injector), followed 15 minutes later by an injection of nicotine (0.03 mg/kg s.c. in 1 ml/kg sterile phosphate buffered saline \[PBS\], pH adjusted to 7.4). The animal was then placed in the non-preferred compartment for 15 minutes. During the other session each animal received an ICV injection of aCSF (2 μl over 20 seconds, followed by a delay of 30 seconds) with an injection of PBS (1 ml/kg s.c.) 15 minutes later. The animal was then placed in the preferred compartment for 15 minutes. These two sessions were counter-balanced and were separated by 3 hours. Members of Group 2 (aCSF-Nic) were treated equivalently to the rats of Group 1; however, each rat received an ICV injection of aCSF (2 μl over 20 seconds) during both sessions followed by nicotine. Members of Group 3 (aCSF-PBS) served as procedural controls and received ICV injections of aCSF (2 μl over 20 seconds) followed 15 minutes later by injections of PBS (1 ml/kg s.c.) during both sessions. Subgroups of 4--8 rats from each group were euthanized 3 hours following the second training session on each of the 5 conditioning days, in order to determine MMP-2, -3, -9 and cortactin levels in the HIP and PFC. The remaining animals from each group were tested for CPP on day 6. All animals in each subgroup were evaluated for MMP and cortactin levels. Naïve home cage control rats were included with each subgroup and their mean MMP and cortactin levels were utilized as the 100% normalized level.

During the post-conditioning phase (day 6) each rat was tested for CPP in a drug-free state. Each rat was placed in the middle compartment and allowed free access to the box for 15 minutes. Time spent in each compartment was measured.

To test for relapse the rats were maintained in their home cages for an additional 5 days without drug injection. On the following day (day 12) each animal was placed in the CPP apparatus in a drug-free state for 15 minutes. Times spent in the nicotine-paired and vehicle-paired compartments were measured. Three hours following behavioral testing these animals were also euthanized and MMP and cortactin levels were measured.

Western immunoblotting
----------------------

Immediately following euthanization (by guillotine) the HIP and PFC from each hemisphere were extracted on ice. The hemispheres were separated by scalpel blade and each hippocampus was isolated using a tephlon-coated spatula and micro scissors (Roboz Instruments). The extreme anterior 1 cm portion of the prefrontal cortex was dissected (vertical cut) from each hemisphere. These tissues were immediately frozen in liquid nitrogen and stored at −80 °C until all samples were collected. Tissues were then weighed and homogenized on ice in homogenization buffer (50 mM Tris HCl pH 7.6, 150 mM NaCl, 5 mM CaCl~2~, 0.05% Brij 35, 0.02% NaN~3~). Homogenates were centrifuged at 12000 RCF for 10 minutes at 4 °C and the supernatant was retained for immunoblotting. 20 μl of the supernatant were mixed 1:1 with 2 × Laemlli sample buffer plus β-mercaptoethanol. Samples were subjected to sodium dodecyl sulfate--polyacrylamide gel electrophoresis and subsequently transferred onto a nitrocellulose membrane. Following transfer, membranes were pre-blocked in 5% milk/Tris-buffered saline before the addition of primary antibody. Membranes were incubated in primary antibody overnight at 4 °C (1:2000, MMP-9 \[Abcam, Cambridge, MA, USA\]; 1:2000, MMP-3 \[RDI, Flanders, NJ, USA\]; 1:1000, MMP-2 \[Chemicon, Temecula, CA, USA\]; 1:2000, cortactin \[Upstate, Charlottesville, VA, USA\]). After rinsing in alternating washes of Tris-buffered saline and TTBS (0.1% Tween 20 in Tris-buffered saline), blots were incubated for 2 hours with a 1:10,000 dilution of horseradish peroxidase-conjugated secondary antibody and rinsed again in Tris-buffered saline/TTBS. The membrane was incubated for 2 minutes in Super-Signal (Pierce, Rockford, IL, USA) and subsequently exposed to the phosphoroimager for visualization. Signal intensity per volume was measured using TotalLab Image Analysis software (AD Instruments Inc., Colorado Springs, CO, USA).

Statistical analysis
--------------------

The comparison of ICV FN439 versus ICV aCSF-infused animals in the acquisition of nicotine-induced CPP on day 6 of training was accomplished by independent *t*-tests (*n* = 5/group). The comparison of HIP MMP levels on each day of training for the aCSF-Nic and aCSF-PBS rats (*n* = 4--8 rats/subgroup) versus naïve home cage controls were analyzed by 2 (groups) × 5 (days of training) ANOVAs, followed by Bonferroni post-hoc tests. Comparisons of aCSF-Nic treated and aCSF-PBS treated groups on each day of training were analyzed by independent *t*-tests. Comparisons of PFC MMP levels for aCSF-Nic and aCSF-PBS groups, each normalized against naïve home cage controls, were also analyzed by 2 (groups) × 5 (days of training) ANOVAs, followed by Bonferroni post-hoc tests. Changes in HIP cortactin levels during CPP training for aCSF-Nic treated and aCSF-PBS treated groups versus home cage control levels were analyzed by the same ANOVA and post-hoc tests. The PFC cortactin levels for these groups were similarly evaluated.

The comparison of percent time spent in the non-preferred chamber by the aCSF-Nic treated rats during initial preference trials versus day 6, and comparing day 6 preference with re-exposure on day 12, was accomplished using paired *t*-tests. Changes in HIP MMP levels during re-exposure compared to naïve home cage control levels were analyzed by independent *t*-tests. Changes in PFC MMP levels during re-exposure compared with naïve home cage control levels were also analyzed by independent *t*-tests. The alpha level for all tests was set at *P* \< 0.01 or greater.

All analyses were performed using GraphPad Prism version 3.02 for Windows (GraphPad Software, San Diego, CA, USA).

Results
=======

Inhibition of MMPs during acquisition of CPP
--------------------------------------------

The results comparing the FN439-Nic and aCSF-Nic groups during each of the 5 CPP training days are presented in [Figure 1](#f1-jen-7-2013-001){ref-type="fig"}. Members of the aCSF-Nic group acquired CPP as determined on test day 6; members of the FN439-Nic group failed to develop CPP and were behaviorally not different from the aCSF-PBS groups of rats. The FN439-Nic group indicated a mean of 392 seconds in the non-preferred compartment prior to CPP training and 306 seconds following training. The aCSF-Nic treated group revealed a mean of 365 seconds in the non-preferred compartment prior to CPP training and 767 seconds following training. Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for the *t*-value.

HIP and PFC MMP levels following each day of CPP training
---------------------------------------------------------

As indicated above, ICV injection of FN439 effectively blocked CPP in members of the FN439-Nic group. These rats also failed to show changes in MMPs different from naïve home cage control levels over the 5 days of training. This confirms the ability of this broad spectrum MMP inhibitor to interfere with CPP contextual-induced MMP expression. Thus, subsequent analyses focused on results from animals assigned to the aCSF-Nic and aCSF-PBS treated groups.

When compared with naïve home cage control levels, there was a significant increase in HIP pro-MMP-2 (72 kDa) in both PBS and nicotine treated groups on days 1 and 4 of CPP training ([Fig. 2A](#f2-jen-7-2013-001){ref-type="fig"}). These groups showed significantly different levels of MMP-2 from one another on days 2 and 5. On day 2 the pro-MMP-2 levels of nicotine treated rats were lower than the saline treated rats but were significantly higher than the saline group on day 5. The middle panel indicates that on day 3 of training there was a significant decrease in pro-MMP-3 (57/59 kDa doublet) by both nicotine and saline treated animals. However, on day 5 of conditioning both nicotine and saline treated animals exhibited a similar increase in pro-MMP-3 protein. The right panel indicates that pro-MMP-9 levels (92/89 kDa doublet) in the nicotine and saline groups were initially below the naïve home cage control level on days 1 and 2, but were significantly elevated in members of the nicotine treated group on days 4 and 5. Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for F values and [Figure 2B](#f2-jen-7-2013-001){ref-type="fig"} for representative bands for each pro-MMP.

Both the saline and nicotine treated groups exhibited significant increases in PFC pro-MMP-2 levels on day 4 ([Fig. 3A](#f3-jen-7-2013-001){ref-type="fig"}, left panel). Similar to the HIP results pro-MMP-3 levels significantly decreased on days 3 and 4 for members of both groups; however, unlike the HIP no late surge in pro-MMP expression was measured on day 5. The levels of pro-MMP-9 in the PFC exhibited little change with a modest decrease by the nicotine treated group on day 2. Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for F values and [Figure 3B](#f3-jen-7-2013-001){ref-type="fig"} for representative bands for each pro-MMP.

HIP and PFC Cortactin levels following CPP training
---------------------------------------------------

HIP cortactin levels decreased significantly in members of both the saline and nicotine treated groups during the first two days of conditioning; they then returned to naïve home cage control levels on days 3 and 4 ([Fig. 4A](#f4-jen-7-2013-001){ref-type="fig"}). Cortactin levels in the nicotine treated rats decreased on day 5 while those of the saline group remained at control level. Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for F values and [Figure 4B](#f4-jen-7-2013-001){ref-type="fig"} for representative bands.

The pattern of PFC cortactin changes ([Fig. 5A](#f5-jen-7-2013-001){ref-type="fig"}) were similar to those seen in the HIP ([Fig. 4A](#f4-jen-7-2013-001){ref-type="fig"}), indicating significant decreases below baseline on days 1 and 2 in both the nicotine and saline treated groups, followed by a return to baseline by day 5. Unlike the HIP, no decline was measured in members of the nicotine group on day 5. Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for F values and [Figure 5B](#f5-jen-7-2013-001){ref-type="fig"} for representative bands.

Conditioned place preference in nicotine treated rats
-----------------------------------------------------

There was a significant increase in preference for the nicotine paired compartment by members of the aCSF-Nic treated group on test day 6 following CPP training (170%) as compared with their precondition preference (100%, [Fig. 6](#f6-jen-7-2013-001){ref-type="fig"}). This preference for the nicotine paired compartment was more robust when the animals were re-exposed to the CPP chambers after 5 days of rest on test day 12 (274%). Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for *t* values.

MMPs in the HIP and PFC following re-exposure
---------------------------------------------

Following re-exposure testing on day 12, HIP pro-MMP-2 and -9 levels in re-exposed and not reexposed groups were not different from naïve home cage control levels, suggesting that these proteins may not be involved in reconsolidation of CPP memory ([Fig. 7A](#f7-jen-7-2013-001){ref-type="fig"}). However, members of both the saline and nicotine treated groups re-exposed to the CPP chamber showed a selective and marked increase in pro-MMP-3 levels. Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for *t* values and [Figure 7B](#f7-jen-7-2013-001){ref-type="fig"} for representative bands for pro-MMP-3.

No significant changes in pro-MMPs were noted in the PFC comparing saline and nicotine treated groups, or between groups re-exposed to the CPP chamber and those that were not re-exposed ([Fig. 8A](#f8-jen-7-2013-001){ref-type="fig"}). Representative bands for active MMP-3 (45 kDa) are shown in [Figure 8C](#f8-jen-7-2013-001){ref-type="fig"}. Both nicotine and saline treated groups showed a significant increase in active MMP-3 levels following re-exposure to the CPP chamber; while no changes were evident in the non-re-exposed groups. This elevation in MMP-3 in the PFC following re-exposure suggests the involvement of MMP-3 in the reconsolidation process. Please refer to [Table 1](#t1-jen-7-2013-001){ref-type="table"} for *t* values.

Cortactin levels in the HIP and PFC following re-exposure
---------------------------------------------------------

No differences were noted in the levels of HIP or PFC cortactin in saline and nicotine treated groups reexposed or not re-exposed (*n* = 4--7/subgroup). Data not shown.

Discussion
==========

Matrix metalloproteinases are known to alter intracellular signaling and influence cytoskeletal protein restructuring.[@b53-jen-7-2013-001]--[@b55-jen-7-2013-001] The actin regulatory protein cortactin is concentrated in dendritic spines of HIP neurons; it is involved in regulating activity dependent changes in dendritic morphology. There appears to be an inverse relationship between MMP activity and cortactin expression, ie. increases in MMP activity often correlate with temporary decreases in cortactin expression.[@b56-jen-7-2013-001] This correlation appears to be necessary in order for synaptic plasticity to occur, followed by increases in the levels of tissue inhibitors of MMPs (TIMPs) designed to terminate MMP enzymatic activity. Reports from our laboratories[@b47-jen-7-2013-001],[@b57-jen-7-2013-001]--[@b62-jen-7-2013-001] and other laboratories[@b55-jen-7-2013-001],[@b63-jen-7-2013-001] have suggested the involvement of MMPs and TIMPs in neural plasticity, memory consolidation, and memory reconsolidation. However, the temporal pattern of MMP expression during learning and drug related memory is not clearly understood.

The present results indicate that transient changes in MMP-2, -3, and -9 occurred in the HIP and PFC during the active phase (rising phase of the acquisition curve when performance is improving) of learning and memory consolidation of nicotine-induced CPP in rats of the aCSF-Nic and aCSF-PBS groups, as compared with naïve home cage control levels (horizontal line, [Fig. 2](#f2-jen-7-2013-001){ref-type="fig"}). Specifically, members of these two groups showed significant elevations in MMP-2 on day 4 of training, while only the nicotine treated group revealed significant elevations on days 1 and 5 of training. Both groups evidenced significant elevations in MMP-3 on day 5; only the nicotine treated group revealed significant elevations in MMP-9 on days 4 and 5. It also appears that MMP-3, but not MMP-2 or -9, may be involved in reactivation of consolidated memory ([Fig. 7](#f7-jen-7-2013-001){ref-type="fig"}). Members of both the nicotine and saline treated groups evidenced significant elevations in MMP-3 during re-exposure. Changes in PFC MMP levels were less dramatic ([Fig. 3](#f3-jen-7-2013-001){ref-type="fig"}). Members of both groups indicated significant changes in MMP-2 on day 4 of training, and significant decreases in MMP-3 on day 3. The nicotine treated group showed significant decreases in MMP-3 on day 4 and MMP-9 on day 2 of training. PFC cortactin levels were depressed in members of both groups on days 1 and 2 ([Fig. 5](#f5-jen-7-2013-001){ref-type="fig"}). Finally, the inhibition of MMP expression by FN439 in rats assigned to the FN439-Nic group resulted in a failure to develop nicotine-induced CPP ([Fig. 1](#f1-jen-7-2013-001){ref-type="fig"}).

MMP expression in the HIP following each day of conditioning suggests the presence of two types of learning. One type appears to be "context dependent" and the other "drug dependent". The nicotine and saline treated rats showed significantly different MMP-2 patterns of expression on days 1 and 5, and in particular MMP-9 on days 4 and 5. These nicotine-induced changes in MMP-9 expression suggest that this protein may be involved in mediating drug related learning. No such differential protein expression patterns were measured with MMP-3 when comparing nicotine and saline treated groups. At the time that animals were presumably finalizing memory consolidation of the CPP task (day 5), HIP MMP-3 levels were significantly elevated in members of both the nicotine and saline treated groups ([Fig. 2A](#f2-jen-7-2013-001){ref-type="fig"}). The nicotine treated group indicated significant elevations in MMP-9 on both days 4 and 5 of training, whereas the saline group showed levels at home cage control values. When the animals were re-exposed to the drug associated context following a 5 day rest period, MMP-3 levels increased significantly in the HIP ([Fig. 7](#f7-jen-7-2013-001){ref-type="fig"}) and PFC ([Fig. 8B](#f8-jen-7-2013-001){ref-type="fig"}), suggesting its involvement in memory reconsolidation. It appears that elevations in MMP-3 may be accompanying the learning that occurs due to handling and the novelty of exposure to the CPP apparatus; this is in contrast to MMP-9 changes, which are more specific to drug related learning, especially late in CPP training. Inhibition of MMP activity by the application of FN439 resulted in the disruption of CPP, thus supporting the hypothesis that MMP activation is required for CPP learning. These results further support the contention that MMPs are involved in the development of CPP for nicotine. However, it is clear that changes in MMP expression also occur due to the experience of being placed in the apparatus. Related to this finding, Brown and colleagues (2008) have reported increases in PFC MMP-9 levels following cocaine primed reinstatement of CPP. The animals used in the present investigation did not receive a drug priming injection during re-exposure to the CPP environment, which may explain the absence of PFC MMP-9 changes.

Decreases in cortactin expression were measured in the HIP and PFC during the first two days of conditioning ([Figs. 4](#f4-jen-7-2013-001){ref-type="fig"} and [5](#f5-jen-7-2013-001){ref-type="fig"}) in both saline and nicotine treated rats; this suggests that the dendritic cytoskeleton underwent restructuring on those days irrespective of drug treatment. It would thus appear that learning, independent of the drug treatment, triggered significant decreases in cortactin cytoskeleton early in training. There were no changes in cortactin when compared with home cage control values during days 3 and 4 of conditioning; however, nicotine treated animals showed a significant decrease on day 5. Thus, by the completion of 5 days of conditioning, synaptic changes may have been complete. There is also the possibility that cytoskeletal protein modifications at the later stages of learning were programmed to occur at a different time point than those selected for tissue collection in this study. It is further possible that cortactin changes may be highly localized in the HIP or PFC, making detection difficult using current gross dissections techniques.

This study focused on the involvement of MMP-2, -3 and -9 in a contextual learning paradigm but other brain MMPs could be involved. A particularly attractive candidate is MMP-7, known to regulate HIP dendritic spine structure.[@b39-jen-7-2013-001] MMP-7 has also been implicated in affecting the structure and function of neurons by modulating synaptic proteins at the active zone where synaptic vesicle recycling is thought to occur.[@b64-jen-7-2013-001]

Our MMP inhibition studies employed FN439, a broad spectrum MMP inhibitor, in order to block the expressions of MMP-2, -3, and -9, and thus their impact on the remodeling process. It should be acknowledged that FN439 is particularly specific to MMP-2 and -9, although it has been used to inhibit MMP-3 as well.[@b65-jen-7-2013-001] Since a limited number of brain MMPs are probably involved in CPP learning, the use of more specific inhibitors to interfere with nicotine-induced CPP may provide more detailed information concerning the respective roles of each MMP. Given the widespread role of MMPs in multiple physiological processes, such an approach is appropriate if MMP inhibition is to be considered as a therapeutic option for the treatment of addictive behaviors.

Conclusion
==========

Studies in humans indicate that adolescent girls are particularly vulnerable to nicotine addiction.[@b5-jen-7-2013-001],[@b6-jen-7-2013-001],[@b66-jen-7-2013-001] Smoking appears to be accompanied by the formation of associations among taste, olfaction, motor, and visual cues; these associations facilitate craving for nicotine. In agreement with findings from humans, the results of this study indicate that nicotine induces CPP in adolescent female rats at a very low dose, much lower than those efficacious in adolescent male rats.[@b27-jen-7-2013-001] Brain MMP expression appears to be important to the synaptic reorganization that accompanies memory consolidation. In order to break these learned associations that maintain nicotine dependence, it may be possible to employ an MMP inhibitor or siRNA that prevents the expression of MMPs, and thus memory reconsolidation that mediates nicotine craving. Taken together the present results support the hypothesis that MMPs are involved in learning of a nicotine-associated contextual memory and that the inhibition of MMP expression may be an efficacious intervention technique to weaken memory reconsolidation. However, it is also clear that animals exposed to such training without nicotine treatment also evidenced similar increases in MMP expression. It is therefore clear that much experimental work remains to be completed in order to gain a full understanding of the relationship among nicotine addiction, brain MMP and cortactin expressions, and memory consolidation/reconsolidation.
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![Mean (SEM) percent shift in preference for the nicotine paired compartment on test day 6 for the icv-Nic and FN439-Nic groups.\
**Notes:** The horizontal line represents the initial preference for the compartment in the absence of drug. *n* = 5 rats in each group. \**P* \< 0.01.](jen-7-2013-001f1){#f1-jen-7-2013-001}

![Changes in HIP MMPs 3 hours following each of 5 days of CPP training. (**A**) HIP MMP proteins were assayed by Western blotting. These data were normalized to naïve protein levels and are represented as mean ± SEM percentage MMP protein levels of naïve home cage control rats (horizontal line). Saline subgroups: *n* = 4--8; Nicotine subgroups: *n* = 5--8; Naïve home cage control groups: *n* = 4--5. \**P* \< 0.01, Comparing each group with naïve home cage control levels. \**P* \< 0.01, Comparing the aCSF-Saline and aCSF-Nic groups. (**B**) Protein densities of representative bands from Western blots of HIP tissues.](jen-7-2013-001f2){#f2-jen-7-2013-001}

![(**A**) Changes in prefrontal cortex MMP levels 3 hours following each of 5 days of CPP training. Terminology is the same as [Figure 2](#f2-jen-7-2013-001){ref-type="fig"}. Saline subgroups: *n* = 4--8; Nicotine subgroups: *n* = 5--8; Naïve home cage control groups: *n* = 4--5. \**P* \< 0.01. (**B**) Protein densities of representative bands from Western blots of PFC tissues.](jen-7-2013-001f3){#f3-jen-7-2013-001}

![Changes in HIP cortactin levels 3 hours following each of 5 days of CPP training. (**A**) These data were normalized to naïve home cage control protein levels and are represented as mean (± SEM) percentage MMP protein levels (horizontal line). Saline subgroups: *n* = 4--8; Nicotine subgroups: *n* = 5--8; Naïve home cage control groups: *n* = 4. \**P* \< 0.01, Comparing each group with naïve home cage control levels. \**P* \< 0.01, Comparing the aCSF-Saline and aCSF-Nic groups. (**B**) Protein densities of representative bands from Western blots HIP tissues.](jen-7-2013-001f4){#f4-jen-7-2013-001}

![(**A**) Prefrontal cortex cortactin levels 3 hours following each of 5 days of CPP training. The horizontal line represents cortactin levels of naïve home cage control animals on each day. Saline subgroups: *n* = 4--8; Nicotine subgroups: *n* = 5--7; Naïve home cage control groups: *n* = 4--7. \**P* \< 0.01. (**B**) Protein densities of representative bands from Western blots PFC tissues.](jen-7-2013-001f5){#f5-jen-7-2013-001}

![Mean (SEM) CPP results for nicotine treated rats following reexposure to the chamber.\
**Notes:** Data were normalized to preconditioning preference and are represented as mean (±SEM) percentage change in preference for the drug paired side. The horizontal line indicates the initial preference for the drug paired compartment. PostCnd = preference for drug paired compartment on day 6 following 5 days of nicotine conditioning. ReExp = preference for drug paired compartment on day 12 following 5 days of rest. PostCnd group: *n* = 5; ReExp group: *n* = 5; \**P* \< 0.01.](jen-7-2013-001f6){#f6-jen-7-2013-001}

![Mean (±SEM) changes in HIP MMP levels following re-exposure to the CPP chamber after 5 days of rest. (**A**) Data were normalized to naïve home cage control protein levels (horizontal line). Rexp = re-exposed to the CPP chamber. NotRxp = not re-exposed to the CPP chamber. Naïve home cage control group: *n* = 4; aCSF-PBS group: *n* = 7; aCSF-Nic group: *n* = 7. \**P* \< 0.01. (**B**) Protein densities of representative bands from Western blots of HIP tissues.](jen-7-2013-001f7){#f7-jen-7-2013-001}

![Mean (±SEM) changes in PFC MMP levels following re-exposure to the CPP chamber on day 12 following 5 days of rest. Refer to [Figure 7](#f7-jen-7-2013-001){ref-type="fig"} for an explanation of terminology. (**A**) There were no significant differences among the levels of pro-MMPs among groups. (**B**) An elevation in the 45 kDa active MMP-3 form was measured in the re-exposed group. \**P* \< 0.01. (**C**) Representative protein bands from Western blots of 45 kDa active MMP-3 measured in PFC tissues.](jen-7-2013-001f8){#f8-jen-7-2013-001}

###### 

Summary of statistical results.

  Data set                     Statistic used    df     *F* or *t* value   Sig. level     Figure
  ---------------------------- ----------------- ------ ------------------ -------------- ------------------------------------------
  **CPP**                                                                                 [1](#f1-jen-7-2013-001){ref-type="fig"}
  FN439-Nic vs. aCSF-Nic       Indep *t*-test    9      4.16               *P* \< 0.01    
  **HIP MMP-2**                                                                           [2A](#f2-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,38   18.44              *P* \< 0.001   
                               Days              4,38   169.68             *P* \< 0.001   
                               Grps × days       4,38   9.45               *P* \< 0.005   
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,39   20.92              *P* \< 0.001   
                               Days              4,39   129.02             *P* \< 0.001   
                               Grps × days       4,39   8.17               *P* \< 0.005   
  **HIP MMP-3**                                                                           [2A](#f2-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,38   --                 Not sig.       
                               Days              4,38   96.96              *P* \< 0.001   
                               Grps × days       4,38   9.07               *P* \< 0.005   
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,41   --                 Not sig.       
                               Days              4,41   72.31              *P* \< 0.001   
                               Grps × days       4,41   12.74              *P* \< 0.001   
  **HIP MMP-9**                                                                           [2A](#f2-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,40   21.65              *P* \< 0.001   
                               Days              4,40   79.70              *P* \< 0.001   
                               Grps × days       4,40   8.84               *P* \< 0.005   
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,45   22.47              *P* \< 0.001   
                               Days              4,45   12.04              *P* \< 0.001   
                               Grps × days       4,45   6.85               *P* \< 0.005   
  **PFC MMP-2**                                                                           [3A](#f3-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,26   14.26              *P* \< 0.001   
                               Days              4,26   170.67             *P* \< 0.001   
                               Grps × days       4,26   12.50              *P* \< 0.001   
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,26   18.93              *P* \< 0.001   
                               Days              4,26   122.24             *P* \< 0.001   
                               Grps × days       4,26   9.40               *P* \< 0.005   
  **PFC MMP-3**                                                                           [3A](#f3-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,35   11.92              *P* \< 0.001   
                               Days              4,35   248.69             *P* \< 0.001   
                               Grps × days       4,35   4.35               *P* \< 0.01    
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,38   20.65              *P* \< 0.001   
                               Days              4,38   198.07             *P* \< 0.001   
                               Grps × days       4,38   4.48               *P* \< 0.005   
  **PFC MMP-9**                                                                           [3A](#f3-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,38   --                 Not sig.       
                               Days              4,38   61.55              *P* \< 0.001   
                               Grps × days       4,38   --                 Not sig.       
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,40   --                 Not sig.       
                               Days              4,40   232/48             *P* \< 0.001   
                               Grps × days       4,40   8.36               *P* \< 0.001   
  **HIP cortactin**                                                                       [4A](#f4-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,40   --                 Not sig.       
                               Days              4,40   8.60               *P* \< 0.001   
                               Grps × days       4,40   11.43              *P* \< 0.001   
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,38   --                 Not sig.       
                               Days              4,38   9.59               *P* \< 0.001   
                               Grps × days       4,38   3.81               *P* \< 0.02    
  **PFC cortactin**                                                                       [5A](#f5-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,35   --                 Not sig.       
                               Days              4,35   --                 Not sig.       
                               Grps × days       4,35   17.91              *P* \< 0.001   
  aCSF-Nic vs. Naïve HCC       2 × 5 ANOVA                                                
                               Groups            1,38   --                 Not sig.       
                               Days              4,38   --                 Not sig.       
                               Grps × days       4,38   25.28              *P* \< 0.001   
  **CPP: aCSF-Nic**                                                                       [6](#f6-jen-7-2013-001){ref-type="fig"}
  Init. pref. vs. Post-cond.   Paired *t*-test   4      5.75               *P* \< 0.01    
  Init. pref. vs. Re-exp       Paired *t*-test   4      8.65               *P* \< 0.001   
  Post-cond. vs. Re-exp        Paired *t*-test   4      5.32               *P* \< 0.01    
  **HIP Re-Exp. MMP-3**                                                                   [7A](#f7-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. naïve HCC       Indep *t*-test    10     7.75               *P* \< 0.001   
  aCSF-Nic vs. naïve HCC       Indep *t*-test    10     7.21               *P* \< 0.001   
  **PFC Re-Exp. MMP-3**                                                                   [8B](#f8-jen-7-2013-001){ref-type="fig"}
  aCSF-PBS vs. naïve HCC       Indep *t*-test    10     12.22              *P* \< 0.001   
  aCSF-Nic vs. naïve HCC       Indep *t*-test    10     11.89              *P* \< 0.001   

**Abbreviations:** aCSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; cond, conditioning; CPP, conditioned place preference; df, degrees of freedom; exp, exposure; grps, groups; HCC, home cage control; HIP, hippocampus; indep, independent; init, initial; MMP, matrix metalloproteinase; Nic, nicotine; *P*, probability; PBS, phosphate buffered saline; PFC, prefrontal cortex; sig, significance (or significant); vs., versus.
